Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2012


The importance of (Bio) Pharmaceutical properties in Successful Drug Design

04 Oct 2012 - 04 Oct 2012 - NHLI, Kensington, London



Bookmark and Share


The pressing challenge pharmaceutical scientists can often be faced with is dealing with drug development candidate molecules with sub-optimal drug delivery or pharmaceutical properties. This symposium brings together international experts from both the pharmaceutical industry and academia to discuss (bio)pharmaceutical properties and strategies to optimise pharmaceutical development and minimise development impact. Small molecule NCE topics include a formulation road map for oral delivery, assessment of CMC developability using material efficiency indices, preclinical assessment of amorphous solid dispersion and case studies of the use of in the development of compounds with poor aqueous solubility, and new insights into the solubilisation, supersaturation and precipitation behaviour of APIs. Biopharmaceutical topics will include microparticle-protein interactions and strategies for optimising delivery and PK of biopharmaceuticals.

Session 1 : Introduction and Chair - Dr Andrew Ratcliffe, Cellzome
10.00   Prof Graham Buckton, Pharmaterials
The form and the formulation - strategy for oral delivery
10.50Dr Andrey Peresypkin, Vertex, USA
Pre-Clinical assessment of CMC developability of drug candidates by using material efficiency indices as the integral part of the translational product development strategy
11.40Dr Mark Saunders, Kuecept
Preclinical assessment of amorphous solid dispersions: friend or foe?
12.30Lunch

Session 2 : Chair - Dr Mo Alavijeh, Pharmidex

13.40Dr David Lyon, Bends Research, USA 
Use of amorphous dispersions in the development of compounds with poor aqueous solubility: Case studies from discovery to commercial
14.30Mr Karl Box, Sirius
Small-scale solubility and dissolution assays; new insights into solubilisation, supersaturation and precipitation behaviour of APIs
15.20Tea
Session 3 : Chair - Dr Kate Brown, Imperial
15.40

Prof Ted Randolp, Centre for Pharmaceutical Biotechnology, USA
Microparticle-Protein interactions: Conformation, cavitation and immune response

16.30Dr Barry Moore, Xstalbio
Strategies for improving delivery, targeting and PK of Biopharmaceuticals




Further information
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!